Munapsys (Acetyl Hexapeptide-1)

Munapsys™ is a next-generation biomimetic peptide, developed through in silico molecular design techniques with the aim of reproducing a relaxing effect on facial muscles in cosmetic and topical form.

Its INCI name is Acetyl Hexapeptide-1, and it stands out in the field of neurocosmetics for a mechanism of action that involves both nerve transmission (the pre-synaptic phase) and the muscular response (the post-synaptic phase).

[INDICE:h2]

What Is Munapsys™? Origin and Design

Munapsys™ was designed through an approach known as in silico design, which uses computational algorithms to simulate interactions between molecules and target proteins. The peptide was optimized to compete with the Munc-18 protein, a key component of the SNARE complex, interfering with the release of acetylcholine, which is responsible for muscle contraction.

It is made up of 99.4% naturally derived ingredients according to the ISO 16128 standard. It comes as a highly soluble aqueous solution and is used at concentrations ranging from 2% to 5%.

How It Works

Pre-synaptic action: acetylcholine release

In the neuromuscular system, contraction is activated by the release of acetylcholine (ACh) from the synaptic vesicles of the motor neuron. This release depends on the correct assembly of the SNARE protein complex, made up of Munc-18, syntaxin, SNAP-25, and VAMP.

Munapsys™ is designed to interfere with the Munc-18 protein, reducing its ability to bind to syntaxin and thereby hindering the formation of the SNARE complex. The result is a lower release of acetylcholine, producing an attenuated, temporary, and reversible effect.

Post-synaptic action: the muscular response

The second characteristic of Munapsys™ concerns the muscles. Unlike Argireline® (Acetyl Hexapeptide-8), which acts only at the level of the nerve signal, this peptide also modulates the expression of genes involved in muscle contraction.

In experimental models using human myocytes, the manufacturer reports a reduction in intracellular calcium mobilization, myosin levels, and the expression of certain contractile genes (ATP2A, TNNC1, MYH1, ACTA1, CACNB1, SCN3A).

This dual level of action — pre- and post-synaptic — is what distinguishes Munapsys™ from other muscle-relaxing peptides on the market.

Data Reported by the Manufacturer

The testing portfolio includes in vitro studies on neuronal and muscle cell models, ex vivo studies on neuron-myofiber co-cultures, and in vivo studies on a group of female volunteers aged between 35 and 55.

The in vitro tests report a reduction in the Munc-18/syntaxin interaction, a decrease in exocytosis in neurons, and lower myosin levels in treated myocytes.

Regarding the clinical test, conducted for 14 days on 18 female volunteers using a 3% cream and evaluated with PRIMOS and VISIA instruments, the manufacturer reports a reduction in skin roughness and the depth of expression lines, with results observable as early as the first week.

As with all patented cosmetic actives, these data come from tests conducted by the ingredient manufacturer and not from independent clinical studies published in peer-reviewed journals. The in vivo test sample was also small (18 subjects) and the duration was short: these findings indicate potential efficacy in a formulation, not definitive proof. The mechanism of action involving the SNARE complex, however, is described in the scientific literature.

Which Wrinkles Does It Target?

Munapsys™ delivers the best results on dynamic wrinkles, which are caused by the repeated movement of the facial muscles:

• glabellar lines, between the eyebrows;
• forehead lines;
• crow’s feet;
• perioral lines.

Its effect is more limited on static wrinkles already structured in the dermis due to the loss of collagen and elastin. In that case, active ingredients that work on the dermal matrix are needed, such as signal peptides or collagen stimulators.

Safety and Tolerability

According to the safety data provided by the manufacturer, Munapsys™ has a zero skin and eye irritation profile in in vitro tests on reconstructed epidermis, no sensitizing potential in the HRIPT, and good stability in formulations. It can therefore also be used on sensitive skin.

Munapsys™ in LeLang’s Multi Peptide Lift

We chose this peptide for Multi Peptide Lift — Botoxil Technology, the intensive facial serum designed to smooth expression lines without resorting to invasive treatments.

Use it as a daily serum before your face cream. It is suitable for anyone aged thirty and over who has pronounced lines in areas affected by facial expressions or prefers a non-invasive approach.

As with all peptides, the effect depends on consistency: when application is discontinued, the muscles gradually return to their usual behavior.

A necessary clarification. Functional cosmetics do not replace aesthetic medicine. A topical peptide acts on the surface, with a much lower and reversible intensity compared with an injectable treatment, which is a medical procedure. Munapsys™ is a valid at-home routine, potentially used alongside aesthetic medicine, or an alternative for those seeking non-invasive solutions — but it is not the same thing and should not be presented as such.

You can also find LeLang products in partner pharmacies throughout Italy.

Frequently Asked Questions

What is the difference between Munapsys™ and Argireline®?

Both act on the transmission of the signal that triggers contraction, but they target different components: Argireline® interferes with SNAP-25, while Munapsys™ acts on Munc-18 and also works further downstream, on the response of the muscle cell.

How long does it take to see results?

The manufacturer’s tests report instrumentally measurable changes within two weeks. For a visible effect, consistent use for several weeks is required.

Is it suitable for sensitive skin?

Yes, tolerability tests did not reveal any irritating or sensitizing potential. During pregnancy and breastfeeding, as with all cosmetic active ingredients, it is advisable to consult a doctor.